This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.
Syneron receives US FDA clearance to market UltraShape for fat cell destruction
Syneron Medical Ltd. (NASDAQ: ELOS) has announced that it has received the United States Food and Drug Administration (FDA) 510(k) clearance to market the UltraShape™ System for non-invasive reduction of abdominal circumference via fat